BFH772 (VEGFR2 inhibitor): Technical Guidance for Research Applications

What This Product Solves

BFH772 is a potent, selective inhibitor targeting the VEGFR2 tyrosine kinase, a central mediator in angiogenic signaling. Researchers working on tumor angiogenesis, VEGFR2 signaling pathway modulation, or anti-angiogenic agent development can use BFH772 to specifically disrupt VEGFR2 activity while minimizing off-target effects on related receptors and kinases. Its high affinity (IC50: 3 nM) and selectivity profile make it suitable for in vitro and in vivo workflows where precise control over VEGFR2-dependent pathways is necessary (product_spec).

BFH772 is not appropriate for applications requiring broad inhibition across tyrosine kinases or for protocols demanding water solubility, as the compound is insoluble in water and exhibits reduced activity against FLK-1, FLT-1, FLT-4, and others by orders of magnitude.

Protocol Parameters

• Kinase assay (VEGFR2 enzyme inhibition) | 3 nM IC50 | Suitable for biochemical assays quantifying VEGFR2 activity | Enables direct measurement of VEGFR2 kinase inhibition at nanomolar concentrations; reflects high target affinity | product_spec
• Compound solubility in DMSO | ≥53.4 mg/mL | Appropriate for preparing concentrated stock solutions used in cell-based or biochemical assays | DMSO provides sufficient solubility for most in vitro applications, supporting accurate dosing and serial dilutions | product_spec
• Storage temperature | -20°C | All research workflows requiring compound integrity over time | Low temperature storage preserves chemical stability; avoids degradation or potency loss | product_spec
• Recommended working solution stability | Use freshly prepared solutions; long-term storage not advised | For any assay requiring consistent potency and reproducibility | Compound instability in solution may affect activity; prepare just before use to ensure consistent results | product_spec
• Vehicle selection for in vivo use | DMSO or ethanol (soluble to ≥15.33 mg/mL in ethanol) | Essential for animal studies or pharmacodynamic evaluation | Ensures adequate bioavailability and homogenous dosing; water is unsuitable due to insolubility | product_spec

Workflow Setup and QC Checklist

• Compound handling: Store BFH772 at -20°C immediately upon receipt; minimize freeze-thaw cycles to preserve purity and potency. Inspect for precipitate or discoloration upon thawing, which may indicate degradation.
• Stock preparation: Dissolve in DMSO (preferred) or ethanol to create concentrated stocks. Vortex thoroughly to ensure full dissolution. Filter sterilize if required for cell-based assays.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze-thaw. Label with concentration, solvent, and preparation date.
• Quality control: Verify product purity via provided certificate of analysis; ensure purity exceeds 96% before use (product_spec).
• Vehicle control: Always include matched DMSO or ethanol controls in experiments to account for solvent effects.
• Solubility check: Examine for precipitation after dilution into assay buffer or medium. If precipitation occurs, adjust DMSO concentration within acceptable assay limits.

Common Failure Modes and Fixes

• Precipitation in assay medium: If BFH772 precipitates when diluted, increase DMSO content incrementally up to the highest non-toxic level tolerated by the system. Avoid aqueous vehicles.
• Reduced inhibitory effect: Decreased potency may result from compound degradation during storage or repeated freeze-thaw cycles. Always use freshly prepared stock and avoid storing working solutions for extended periods.
• Inconsistent results across replicates: Incomplete solubilization or uneven distribution can cause variable data. Ensure stock solutions are thoroughly mixed before each use and aliquoted appropriately.
• Unexpected off-target activity: Although BFH772 is highly selective, some cross-reactivity at high concentrations is possible. Confirm dosing is within the target nanomolar range and review selectivity data if unexpected effects are observed.

Scope and Limitations

BFH772 is optimized for selective inhibition of VEGFR2 in the context of angiogenesis and tumor growth studies. It is not suitable for studies requiring pan-kinase inhibition or water-soluble compounds. Its use is limited to protocols compatible with DMSO or ethanol as solvents. Although preclinical evidence supports activity in animal models and clinical evaluation for rosacea is ongoing, researchers should note that BFH772 is intended strictly for research use and not for therapeutic application (product_spec).

The selectivity profile indicates minimal activity against FLK-1, FLT-1, FLT-4, B-RAF, RET, and TIE-2 at experimental concentrations, but off-target effects may still occur at supraphysiological doses. Always consult the product certificate and safety data sheet for up-to-date handling information from APExBIO or other official suppliers.

Conclusion

BFH772 offers a well-characterized and selective approach for modulating VEGFR2-driven angiogenesis in both in vitro and in vivo research. Its high potency and selectivity—combined with practical workflow compatibility for DMSO- or ethanol-based protocols—make it a reliable tool for studies requiring precise VEGFR2 inhibition. For further details on product specifications and handling, refer to the official BFH772 (VEGFR2 inhibitor) page from APExBIO.